Screening for ovarian cancer

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 16, Issue 4, 2002, Pages 469-482

  Menon, Usha ^a   Jacobs, Ian ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Department of Obstetrics ^*

Author keywords

Ovarian neoplasm; Screening early detection

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

CANCER CONTROL; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CLINICAL TRIAL; HIGH RISK POPULATION; HUMAN; MORBIDITY; OVARY CANCER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; ULTRASOUND; UNITED KINGDOM; UNITED STATES; ADULT; AGED; BLOOD; CANCER STAGING; CONTROLLED CLINICAL TRIAL; FEMALE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; CA-125 ANTIGEN; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0036676761     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.2002.0297     Document Type: Article

References (45)

1. Office for National Statistics. Cancer Statistics: Registrations. Series MBI no.24. HMSO, 1997.
2. Jacobs IJ, Skates SJ, MacDonald N et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999; 353: 1207-1210.
3. van Nagell JR Jr, De Priest PD, Reedy MB et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecologic Oncology 2000; 77: 350-356.
4. Sato S, Yokoyama Y, Sakamoto T et al. Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer 2000; 89: 582-588.
5. DePriest PD, Gallion HH, Pavlik EJ et al. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecologic Oncology 1997; 65: 408-414.
6. van Nagell JR Jr, Gallion HH, Pavlik EJ & De Priest PD. Ovarian cancer screening. Cancer 1995; 76 (supplement 10): 2086-2091.
7. Hayashi H, Yaginuma Y, Kitamura S et al. Bilateral oophorectomy in asymptomatic women over 50 years old selected by ovarian cancer screening. Gynecologic and Obstetric Investigation 1999; 47: 58-64.
8. Tabor A, Jensen FR, Bock JE & Hogdall CK. Feasibility study of a randomised trial of ovarian cancer screening. Journal of Medical Screening 1994; 1: 215-219.
9. Campbell S, Bhan V, Royston P et al. Transabdominal ultrasound screening for early ovarian cancer. British Medical Journal 1989; 299: 1363-1367.
10. Millo R, Facca MC & Alberico S. Sonographic evaluation of ovarian volume in postmenopausal women: a screening test for ovarian cancer? Clinical Experimental Obstetrics and Gynecology 1989; 16: 72-78.
11. Goswamy RK, Campbell S & Whitehead MI. Screening for ovarian cancer. Clinical Obstetrics and Gynaecology 1983; 10: 621-643.
12. Kurjak A, Shalan H, Kupesic S et al. An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography. Journal of Ultrasound Medicine 1994; 13: 295-301.
13. Vuento MH, Pirhonen JP, Makinen JI et al. Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer 1995; 76: 1214-1218.
14. Parkes CA, Smith D, Wald NJ & Bourne TH. Feasibility study of a randomised trial of ovarian cancer screening among the general population. Journal of Medical Screening 1994; 1: 209-214.
15. Holbert TR. Screening transvaginal ultrasonography of postmenopausal women in a private office setting. American Journal of Obstetrics and Gynecology 1994; 170: 1699-1703.
16. Schincaglia P, Brondelli L, Cicognani A et al. A feasibility study of ovarian cancer screening: does fine-needle aspiration improve ultrasound specificity? Tumori 1994; 80: 181-187.
17. Einhorn N, Sjovall K, Knapp RC et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstetrics and Gynecology 1992; 80: 14-18.
18. Jacobs IJ, Skates S, Davies AP et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. British Medical Journal 1996; 313: 1355-1358.
19. Jacobs I, Davies AP, Bridges J et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. British Medical Journal 1993; 306: 1030-1034.
20. Jacobs I, Stabile I, Bridges J et al. Multimodal approach to screening for ovarian cancer. Lancet 1988; 1: 268-271.
21. Grover S, Quinn MA, Weideman P et al. Screening for ovarian cancer using serum CA125 and vaginal examination: report on 2550 females. International Journal of Gynecologic Cancer 1995; 5: 291-295.
22. Adonakis GL, Paraskevaidis E, Tsiga S et al. A combined approach for the early detection of ovarian cancer in asymptomatic women. European Journal of Obstetrics Gynecology and Reproductive Biology 1996; 65: 221-225.
23. Skates SJ & Singer DE. Quantifying the potential benefit of CA 125 screening for ovarian cancer. Journal of Clinical Epidemiology 1991; 44: 365-380.
24. Skates SJ, Xu FJ, Yu YH et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995; 76 (supplement 10): 2004-2010.
25. Skates SJ, Pauler DK & Jacobs IJ. Screening based on the risk of cancer calculation from Bayesian hierarchical change-point and mixture models of longitudinal markers. Journal of the American Statistical Association 2001; 96: 429-439.
26. Randomised trial of screening for ovarian cancer (protocol). Gynaecological Oncology Unit, Bart's and the London, Queen Mary's School of Mediciine and Dentistry; London; United Kingdom; 1996.
27. UK Collaborative Trial of Ovarian Cancer Screening (protocol).: Gynaecological Oncology Unit, Bart's and the London Queen Mary's School of Medicine and Dentistry; London; United Kingdom; 2000.
28. Menon U, Talaat A, Rosenthal AN et al. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. British Journal of Obstetrics and Gynaecology 2000; 107: 165-169.
29. Menon U, Talaat A, Jeyarajah AR et al. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. British Journal of Cancer 1999; 80: 1644-1647.
30. Xu Y, Shen Z, Wiper DW et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. Journal of the American Medical Association 1998; 280: 719-723.
31. Bailey CL, Ueland FR, Land GL et al. The malignant potential of small cystic ovarian tumors in women over 50 years of age. Gynecologic Oncology 1998; 69: 3-7.
32. DePriest PD, Shenson D, Fried A et al. A morphology index based on sonographic findings in ovarian cancer. Gynecologic Oncology 1993; 51: 7-11.
33. Cohen LS, Escobar PF, Scharm C et al. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecologic Oncology 2001; 82: 40-48.
34. Dorum A, Heimdal K, Lovslett K et al. Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstetricia et Gynecologica Scandinavica 1999; 78: 906-911.
35. Karlan BY, Baldwin RL, Lopez-Luevanos E et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. American Journal of Obstetrics Gynecology 1999; 180: 917-928.
36. Bourne TH, Campbell S, Reynolds KM et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. British Medical Journal 1993; 306: 1025-1029.
37. Weiner Z, Beck D, Shteiner M et al. Screening for ovarian cancer in women with breast cancer with transvaginal sonography and color flow imaging. Journal of Ultrasound Medicine 1993; 12: 387-393.
38. Karlan BY, Raffel LJ, Crvenkovic G et al. A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design, and early results. American Journal of Obstetrics and Gynecology 1993; 169: 494-501.
39. Muto MG, Cramer DW, Brown DL et al. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. Gynecologic Oncology 1993; 51: 12-20.
40. Schwartz PE, Chambers JT & Taylor KJ. Early detection and screening for ovarian cancer. Journal of Cell Biochemistry 1995; 23 (supplement): 233-237.
41. Dorum A, Kristensen GB, Abeler VM et al. Early detection of familial ovarian cancer. European Journal of Cancer 1996; 32A: 1645-1651.
42. Menkiszak J, Jakubowska A, Gronwald J et al. [Hereditary ovarian cancer: summary of 5 years of experience]. Ginekologia Polska 1998; 69: 283-287.
43. Belinson JL, Okin C, Casey G et al. The familial ovarian cancer registry: progress report. Cleveland Clinics Journal of Medicine 1995; 62: 129-134.
44. Gohagan JK, Prorok PC, Hayes RB & Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Controlled Clinical Trials 2000; 21 (supplement 6): 251S-272S.
45. Prorok PC, Andriole GL, Bresalier RS et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials 2000; 21 (supplement 6): 273S-309S.